Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nagahiro Saijo

Showing results (1-10 of 238) with videos related to

Pageof 24
Sort By:
Cancer Science|October 27, 2004
What are the reasons for negative phase III trials of molecular-target-based drugs?Nagahiro Saijo
Internal Medicine (Tokyo, Japan)|November 5, 2002
Translational study in cancer researchNagahiro Saijo
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|March 26, 2003
[Medical oncology in Japan]Nagahiro Saijo
Cancer Science|June 1, 2006
Recent trends in the treatment of advanced lung cancerNagahiro Saijo
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[History of cancer chemotherapy; from cytotoxic drugs to molecular targeted therapy]Nagahiro Saijo
Cancer Research and Treatment|April 14, 2012
Present status and problems on molecular targeted therapy of cancerNagahiro Saijo
Clinical Lung Cancer|December 9, 2003
Irinotecan Combined with Radiation Therapy for Patients with Stage III Non-Small-Cell Lung Cancer: Current TrialsNagahiro Saijo
Nature Clinical Practice. Oncology|November 3, 2005
What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?Nagahiro Saijo
Japanese Journal of Clinical Oncology|July 24, 2010
Progress in cancer chemotherapy with special stress on molecular-targeted therapyNagahiro Saijo
Yonsei Medical Journal|December 11, 2012
The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncologyNagahiro Saijo
Pageof 24

Showing results (1-10 of 238) with videos related to

Sort By:
Pageof 24
Cancer Science|October 27, 2004
What are the reasons for negative phase III trials of molecular-target-based drugs?Nagahiro Saijo
Internal Medicine (Tokyo, Japan)|November 5, 2002
Translational study in cancer researchNagahiro Saijo
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|March 26, 2003
[Medical oncology in Japan]Nagahiro Saijo
Cancer Science|June 1, 2006
Recent trends in the treatment of advanced lung cancerNagahiro Saijo
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[History of cancer chemotherapy; from cytotoxic drugs to molecular targeted therapy]Nagahiro Saijo
Cancer Research and Treatment|April 14, 2012
Present status and problems on molecular targeted therapy of cancerNagahiro Saijo
Clinical Lung Cancer|December 9, 2003
Irinotecan Combined with Radiation Therapy for Patients with Stage III Non-Small-Cell Lung Cancer: Current TrialsNagahiro Saijo
Nature Clinical Practice. Oncology|November 3, 2005
What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?Nagahiro Saijo
Japanese Journal of Clinical Oncology|July 24, 2010
Progress in cancer chemotherapy with special stress on molecular-targeted therapyNagahiro Saijo
Yonsei Medical Journal|December 11, 2012
The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncologyNagahiro Saijo
Pageof 24